Return to Positive Core Revenue Growth
Total Q2 revenue of $224.7M with core revenue growth of 2.9% (foreign currency +0.9%; divestitures/discontinued products headwind -6.6%).
Food Safety Segment Strength
Food Safety revenue of $165.6M with core revenue growth of 4.1%; indicator testing/culture media and sample collection were key drivers, and PetriFilm returned to high-single-digit growth.
Genomics and Regional Performance
Global genomics core revenue growth accelerated to 6% in the quarter. Regional core growth led by LatAm (high-single-digits); U.S./Canada mid-single-digits; APAC low-single-digits; EMEA slight decline (low-single-digits).
Margin and Profitability Improvement
Adjusted EBITDA of $48.7M (margin 21.7%) — a sequential improvement of ~470 basis points. Adjusted net income $22.6M and adjusted EPS $0.10 versus $9.4M and $0.04 in the prior quarter (adjusted net income up ~140%, EPS up 150%).
Gross Margin Recovery
Reported gross margin improved to 47.5% (sequential improvement of ~210 bps); excluding integration/restructuring items gross margin was 50.3%.
Cost Actions and Operational Savings
Q2 cost structure improvements implemented are expected to deliver approximately $20M of annualized savings; a headcount reduction contributed to margin expansion.
Petrifilm Integration Progress
Petrifilm integration remains on track for the previously disclosed 2027 timeline — late-stage production testing completed well and initial product validation underway; ability to manufacture Petrifilm plates has been demonstrated.
Balance Sheet and Cashflow Improvements
Gross debt of $800M (68% fixed) and cash of $145.3M; prior Cleaners & Disinfectants divestiture enabled $100M debt paydown. Q2 free cash flow was $7.8M, improving $20.9M from Q1. Management expects FY CapEx ~$50M and routine CapEx trending to 3–4% of revenue.
Guidance Raised
Management raised full-year fiscal 2026 guidance: revenue now expected $845M–$855M and adjusted EBITDA approximately $175M, reflecting Q2 outperformance.
Leadership and Commercial Execution
Strengthened senior leadership (new CFO, CCO, and other senior hires) and implemented process-driven commercial changes (weekly LBE forecasting, solutions-based selling) credited with improved predictability and sales execution.